Drug-mediated inactivation of cytochrome P450

Clinical and Experimental Pharmacology and Physiology

Volumn 24, Issue 7, 1997, Pages 465-470

  Murray, Michael ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

Cytochrome P450; Enzyme inactivation; Mechanism based inhibition; Metabolite intermediate complexation

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; AZITHROMYCIN; CARCINOGEN; CLARITHROMYCIN; CONTRACEPTIVE AGENT; CYTOCHROME P450 ISOENZYME; ERYTHROMYCIN; ETHCHLORVYNOL; ETHINYLESTRADIOL; FURAFYLLINE; ICOSANOID; JOSAMYCIN; MACROLIDE; METHOXSALEN; MONOAMINE OXIDASE INHIBITOR; ORPHENADRINE; PHENYTOIN; PSYCHOTROPIC AGENT; ROKITAMYCIN; ROXITHROMYCIN; SECOBARBITAL; SPIRAMYCIN; STEROID; TIENILIC ACID; TROLEANDOMYCIN; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

ADVERSE DRUG REACTION; BIOTRANSFORMATION; CHOLESTASIS; COMPLEX FORMATION; COVALENT BOND; DRUG METABOLISM; ENZYME INACTIVATION; ENZYME SPECIFICITY; ENZYME SUBSTRATE COMPLEX; HUMAN; METABOLITE; NONHUMAN; OXIDATION; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0030918475     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1997.tb01228.x     Document Type: Review

References (62)

1. Nebert DW, Gonzalez FJ. P450 genes. Structure, evolution and regulation. Annu. Rev. Biochem. 1987; 56: 945-93.
2. Nelson DR, Koymans L, Kamataki T et al. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 1-42.
3. Shou M, Korzekwa KR, Crespi CL et al. The role of 12 cDNA-expressed human, rodent, and rabbit cytochromes P450 in the metabolism of benzo[a]pyrene and benzo[a]pyrene trans-7,8-dihydrodiol. Mol. Carcinog. 1994; 10: 159-68.
4. Gu L, Gonzalez FJ, Kalow W, Tang BK. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 1992; 2: 73-7.
5. Patten C, Thomas PE, Guy R et al. Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. Chem. Res. Toxicol. 1993; 6: 511-18.
6. Yamazaki H, Inui Y, Yun C-H et al. Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 1992; 13: 1789-94.
7. Goldstein JA, Faletto MB, Romkes-Sparks M et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994; 33: 1743-52.
8. Miners JO, Rees DLP, Valente L et al. Human hepatic Cytochrome P450 2C9 catalyses the rate-limiting pathway of torsemide metabolism. J. Pharmacol. Exp. Ther. 1995; 272: 1076-81.
9. Gonzalez FJ. The molecular biology of cytochrome P450s. Pharmacol. Rev. 1989; 40: 243-88.
10. Guengerich FP. Characterisation of human microsomal cytochrome P-450 enzymes. Annu. Rev. Pharmacol. Toxicol. 1989; 29: 241-64.
11. Koymans L, Vermeulen NPE, van Acker SABE et al. A predictive model for substrates of cytochrome P450-debrisoquine (2D6). Chem. Res. Toxicol. 1992; 5: 211-19.
12. Guengerich FP, Kim D-H, Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol. 1991; 4: 168-79.
13. Shimada T, Yamazaki H, Mimura M et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidations of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 1994; 270: 414-23.
14. Wrighton SA, Ring BJ, Watkins PB, VandenBranden M. Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol. Pharmacol. 1989; 36: 97-105.
15. Guengerich FP. Human cytochrome P450 enzymes. In: Ortiz de Montellano PR (ed.). Cytochrome P450: Structure, Mechanism and Biochemistry, 2nd edn. Plenum Press, New York, 1995; 473-535.
16. Eichelbaum M. Defective oxidation of drugs: Pharmacokinetic and therapeutic implications. Clin. Pharmacokinet. 1982; 7: 1-22.
17. Pessayre D, Larrey D, Vitaux J et al. Formation of an inactive cytochrome P-450 Fe(II)-metabolite complex after administration of troleandomycin in humans. Biochem. Pharmacol. 1982; 31: 1699-704.
18. Larrey D, Funck-Brentano C, Breil P et al. Effects of erythromycin on hepatic drug-metabolising enzymes in humans. Biochem. Pharmacol. 1983; 32: 1063-8.
19. Murray M, Reidy GF. Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacol. Rev. 1990; 42: 85-101.
20. Ortiz de Montellano PR. In: Ortiz de Montellano PR (ed.). Cytochrome P450: Structure, Mechanism and Biochemists, 2nd edn. Plenum Press, New York, 1995; 245-302.
21. Rando RR. Mechanism-based enzyme inactivators. Pharmacol. Rev. 1984; 36: 111-42.
22. Osawa Y, Pohl LR. Covalent bonding of the prosthetic heme to protein: A potential mechanism for the suicide inactivation or activation of hemoproteins. Chem. Res. Toxicol. 1989; 2: 131-41.
23. Ortiz de Montellano PR, Yost GS, Mico BA et al. Destruction of cytochrome P-450 by 2-isopropyl-4-pentenamide and methyl 2-isopropyl-4-pentenoate: Mass spectrometric characterisation of prosthetic heme adducts and nonparticipation of epoxide metabolites. Arch. Biochem. Biophys. 1979; 197: 524-33.
24. Ortiz de Montellano PR, Mico BA. Destruction of cytochrome P-450 by ethylene and other olefins. Mol. Pharmacol. 1980; 18: 128-35.
25. Ortiz de Montellano PR, Kunze KL. Self-catalysed inactivation of hepatic cytochrome P-450 by ethynyl substrates. J. Biol. Chem. 1980; 255: 5578-84.
26. b: A mechanistic reappraisal. Mol. Pharmacol. 1989; 35: 10-17.
27. White INH. Biliary excretion of green pigments produced by norethindrone in the rat. Biochem. Pharmacol. 1982; 31: 1337-42.
28. Guengerich FP. Oxidation of 17α-ethynylestradiol by human liver cytochrome P-450. Mol. Pharmacol. 1988; 33: 500-8.
29. Guengerich FP. Mechanism-based inactivation of human liver cytochrome P-450 IIIA4 by gestodene. Chem. Res. Toxicol. 1990; 3: 363-71.
30. Ortiz de Montellano PR, Beilan HS, Mathews JM. Alkylation of the prosthetic heme in cytochrome P-450 during oxidative metabolism of the sedative-hypnotic ethchlorvynol. J. Med. Chem. 1982; 25: 1174-9.
31. Decker CJ, Rashed MS, Baillie TA et al. Oxidative metabolism of spironolactone: Evidence for the involvement of electrophilic thiosteroid species in drug-mediated destruction of rat hepatic cytochrome P-450. Biochemistry 1989; 28: 5128-36.
32. Riddick DS, Marks GS. Irreversible binding of heme to microsomal protein during inactivation of cytochrome P-450 by alkyl analogues of 3,5-diethoxycarbonyl-1,4-dihydro-2,4,6-methylpyridine. Biochem. Pharmacol. 1990; 40: 1915-21.
33. Lopez-Garcia MP, Dansette PM, Mansuy D. Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450: Inactivation of yeast-expressed human liver cytochrome P-450 2C9 by tienilic acid. Biochemistry 1994; 33: 166-75.
34. Halpert JR. Covalent modification of lysine during the suicide inactivation of rat liver cytochrome P-450 by chloramphenicol. Biochem. Pharmacol. 1981; 30: 875-81.
35. Tinel M, Belghiti J, Descatoire V et al. Inactivation of human liver cytochrome P-450 by the drug methoxsalen and other psoralen derivatives. Biochem. Pharmacol. 1987; 36: 951-5.
36. Hoag MLP, Trevor AJ, Kalir A, Castagnoli N Jr. Phencyclidine iminium ion NADPH-dependent metabolism, covalent binding to macromolecules, and inactivation of cytochrome(s) P450. Drug Metab. Dispos. 1987; 15: 648-52.
37. Holley AE, Frater Y, Gibbs AH et al. Isolation of two N-monosubstituted protoporphyrins, bearing either the whole drug or a methyl group on the pyrrole nitrogen atom, from liver of mice given griseofulvin. Biochem. J. 1991; 274: 843-8.
38. Sharma U, Roberts ES, Hollenberg PF. Inactivation of cytochrome P4502B1 by the monoamine oxidase inhibitors R-(-)-deprenyl and clorgyline. Drug Metab. Dispos. 1996; 24: 669-75.
39. Kunze KL, Trager WF. Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem. Res. Toxicol. 1993; 6: 649-56.
40. Clarke SE, Ayrton AD, Chenery RJ. Characterisation of the inhibition of P4501A2 by furafylline. Xenobiotica 1994; 24: 517-26.
41. Halpert J, Naslund B, Betner I. Suicide inactivation of rat liver cytochrome P-450 by chloramphenicol in vivo and in vitro. Mol. Pharmacol. 1983; 23: 445-52.
42. Chiba M, Nishime JA, Lin JH. Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754 394, an investigational human immune deficiency virus protease inhibitor. J. Pharmacol. Exp. Ther. 1995; 275: 1527-34.
43. Mansuy D, Rouer E, Bacot C et al. Interaction of aliphatic N-hydroxylamines with microsomal cytochrome P450: Nature of the different derived complexes and inhibitory effects on monoxygenases activities. Biochem. Pharmacol. 1978; 27: 1229-37.
44. Lindeke B, Paulsen U, Anderson E. Cytochrome P-455 complex formation in the metabolism of phenylalkylamines-IV. Spectral evidences for metabolic conversion of methamphetamine to N-hydroxyamphetamine. Biochem. Pharmacol. 1979; 28: 3629-35.
45. Bast A, Noordhoek J. Spectral interaction of orphenadrine and its metabolites with oxidised and reduced hepatic microsomal cytochrome P-450 in the rat. Biochem. Pharmacol. 1982; 31: 2745-53.
46. Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. Clin. Pharmacokinet. 1992; 23: 106-31.
47. Azanza JR, Catalan M, Alvarez MP et al. Possible interaction between cyclosporin and josamycin: A description of three cases. Clin. Pharmacol. Ther. 1992; 51: 572-5.
48. Gharbi-Benarous J, Delaforge M, Jankowski CK, Girault J-P. A comparative NMR study between the macrolide antibiotic roxithromycin and erythromycin A with different biological properties. J. Med. Chem. 1991; 34: 1117-25.
49. Ohmori S, Ishii I, Kuriya S-I et al. Effects of clarithromycin and its metabolites on the mixed function oxidase system in hepatic microsomes of rats. Drug Metab. Dispos. 1993; 21: 358-63.
50. Sartori E, Delaforge M, Mansuy D. In vitro interaction of rat liver cytochromes P-450 with erythromycin, oleandomycin and erythralosamine derivatives. Biochem. Pharmacol. 1989; 38: 2061-8.
51. Labout JJM, Thijssen CT, Keijser GGJ, Hespe W. Difference between single and multiple dose pharmacokinetics of orphenadrine in man. Eur. J. Clin. Pharmacol 1982; 21: 343-50.
52. Reidy GF, Mehta I, Murray M. Inhibition of oxidative drug metabolism by orphenadrine: In vitro and in vivo evidence for isozyme-specific complexation of cytochrome P-450 and inhibition kinetics. Mol. Pharmacol. 1989; 35: 736-43.
53. Murray M. Metabolite intermediate complexation of microsomal cytochrome P450 2C11 in male rat liver by nortriptyline. Mol. Pharmacol. 1992; 42: 931-8.
54. Bensoussan C, Delaforge M, Mansuy D. Particular ability of cytochromes P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs. Biochem. Pharmacol. 1995; 49: 591-602.
55. Wilkinson CF, Murray M, Marcus CB. Interactions of methylene-dioxyphenyl compounds with cytochrome P-450 and effects on microsomal oxidation. Rev. Biochem. Toxicol. 1984; 6: 27-63.
56. Mesnil M, Testa B, Jenner P. In vitro inhibition by stiripentol of rat brain cytochrome P-450-mediated naphthalene hydroxylation. Xenobiotica 1988; 18: 1097-106.
57. Levy RH, Loiseau P, Guyot M et al. Stiripentol kinetics in epilepsy: Nonlinearity and interactions. Clin. Pharmacol. Ther. 1984; 36: 661-9.
58. Hines RN, Prough RA. The characterization of an inhibitory complex formed with cytochrome P-450 and a metabolite of 1,1-disubstituted hydrazines. J. Pharmacol. Exp. Ther. 1980; 214: 80-6.
59. Muakkassah SF, Bidlack WR, Yang WCT. Reversal of the effects of isoniazid on hepatic cytochrome P-450 by potassium ferricyanide. Biochem. Pharmacol. 1982; 31: 249-51.
60. Moloney SJ, Snider RJ, Prough RA. The interactions of hydrazine derivatives with rat hepatic cytochrome P-450. Xenobiotica 1984; 14: 803-14.
61. Murray M, Wilkinson CF, Marcus C, Dube CE. Structure-activity relationships in the interactions of alkoxymethylenedioxyphenylbenzene derivatives with rat hepatic microsomal mixed-function oxidases in vivo. Mol. Pharmacol. 1983; 24: 129-36.
62. Murray M, Zaluzny L, Farrell GC. Selective reactivation of steroid hydroxylases following dissociation of the isosafrole metabolite complex with rat hepatic cytochrome P-450. Arch. Biochem. Biophys. 1986; 251: 471-8.